FEB 01, 2019 10:11 PM PST

Re-purposing Anti-rejection Drug for Liver Cancers

WRITTEN BY: Nouran Amin

Scientists at the University of Pittsburgh School of Medicine have identified a molecular pathway in liver that can allow an anti-rejection drug to be repurposed for the treatment of certain liver cancers. "Current liver cancer therapies increase the likelihood of survival only by 3 or 4 months, so taking a precision medicine approach to identify the right patient could allow us to repurpose existing drugs to improve treatment success," says Satdarshan Monga, M.D., professor of pathology and founding director of the Pittsburgh Liver Research Center at Pitt's School of Medicine.

Learn more about liver cancers:

"What we've found is that liver cancers with a specific mutation in the β-catenin gene are possibly more susceptible to rapamycin, a commonly used anti-rejection medication in transplantation," says Monga. "We think this gives us a new precision medicine approach to develop therapies for liver cancer, which often are very resistant to treatment."

These are mouse liver tissues showing cells surrounding the central vein with active mTOR (red) and glutamine synthetase (green) being present in the same cells (yellow).

Credit: Cell Reports/University of Pittsburgh

Investigation of the molecular pathway began with measurements of high levels of a protein called mTOR--a nutrition and energy sensor crucial to cellular metabolism. The protein was present in the same cells where β-catenin was known to be active. This encouraged the researchers to see if the two proteins were functionally linked by creating a mouse model of liver cancer. They added a drug called rapamycin, a known immunosuppressant of mTOR, and found that the tumors decreased in size. This confirmed that mTOR palsy a major role in cancer growth of the liver. "I like to say these tumors are mTOR addicted," said Monga, who is senior author of the study as well as an investigator at the McGowan Institute of Regenerative Medicine and the UPMC Hillman Cancer Center. "Activating mTOR kicks up the protein-making factories in these cells, giving them the resources to divide and grow."

Results of the study were published in Cell Metabolism.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 11, 2020
Cardiology
APR 11, 2020
Cell Transplant Repairs Brain After Stroke
Using cell therapy, researchers from Lund University in Sweden have successfully restored mobility and a sense of touch ...
APR 15, 2020
Neuroscience
APR 15, 2020
How Magic Mushrooms Restructure the Brain
For some time now, researchers have suspected that psilocybin, the hallucinogen chemical present in ‘magic mushroo ...
APR 18, 2020
Cancer
APR 18, 2020
A New Double Threat Against Skin Cancer
Skin cancer is one of the most common cancers in America.  One of the most aggressive forms of cancer is melanoma, ...
APR 17, 2020
Cannabis Sciences
APR 17, 2020
Does CBD Really Ease Arthritis Pain?
Cannabis products are increasingly used to treat chronic pain from arthritis. As its non psychoactive ingredient, cannab ...
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
MAY 26, 2020
Drug Discovery & Development
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
Loading Comments...